LAVA Therapeutics (NASDAQ:LVTX) Posts Earnings Results, Beats Estimates By $0.18 EPS

LAVA Therapeutics (NASDAQ:LVTX) posted its quarterly earnings data on Friday. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.18, Zacks reports. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.40 million.

LAVA Therapeutics Price Performance

Shares of LAVA Therapeutics stock opened at $1.29 on Friday. LAVA Therapeutics has a one year low of $0.85 and a one year high of $3.57. The business’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.37. The stock has a market capitalization of $33.92 million, a P/E ratio of -1.25 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. JMP Securities restated a “market perform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs cut LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 target price (down previously from $2.00) on shares of LAVA Therapeutics in a research note on Thursday, February 27th. Leerink Partners reissued a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Finally, Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.17.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.